Open AccessEffect of the preparation Ingavirin® (imidazolyl ethanamide pentandioic acid) on the interferon status of cells under conditions of viral infection
Author(s) -
Thomas Aschacher,
Ашахер Томас,
Artem Krokhin,
Artem Krokhin,
Irina Kuznetsova,
Irina Kuznetsova,
Johannes Längle,
Ленгл Йоханнес,
Vladimir E. Nebolsin,
Vladimir E. Nebolsin,
Andrey I. Egorov,
Егоров Андрей,
Michael Bergmann,
Бергманн Михаэль
Publication year - 2016
Publication title -
èpidemiologiâ i infekcionnye bolezni
Language(s) - English
Resource type - Journals
eISSN - 2411-3026
pISSN - 1560-9529
DOI - 10.17816/eid40907
Subject(s) - interferon , virology , effector , innate immune system , virus , antiviral drug , influenza a virus , immune system , pathogen , biology , viral infection , immunology
Ingavirin® (imidazolyl ethanamide pentandioic acid) is an original antiviral drug, which is used in Russia for treatment and profilaxis of influenza and other acute viral infections. We confirmed that imidazolyl ethanamide pentandioic acid (IEPA), not being interferon inducer itself, enhances synthesis of both interferon-a/fi receptors (IFNAR) to interferone and cell sensitivity to interferone signalling, which was suppressed by NS1 protein - pathogen factor of influenza virus. IEPA is able to promote antiviral effector proteins PKR and MxA in infected cells, in opposition to interferon system suppression by influenza virus. Theoretical ground of clinical efficacy of Ingavirine® could be confirmed by obtained data of influence to innate immune system during viral infection.